Affinity between the PCR and antigen tests and their positivity for Covid-19 in Colombia

Afinidad entre las pruebas PCR y Antígeno, y su positivad para COVID-19 en Colombia

Main Article Content

Jorge Enrique Díaz Pinzón

Abstract

Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19) has spread rapidly around the world since it emerged in Wuhan, China, in late 2019. Objective: to describe the positivity rates of samples tested for SARS-CoV-2. Methodology: the research focused on PCR and antigen tests processed for COVID-19, using the information released by the National Institute of Health between January 1 and March 31 2021. Results: the highest positivity rate for PCR testing for each month between January to March 2021 in Colombia was found on the following days: January 12: 56.3%, January 7: 44.9%, January 6: 45.1%, January 5: 43.7%, January 2: 38.1%, March 24: 35.2% and March 26: (31.3%. The days with the highest percentage of positive cases found by antigen testing for each month from January to March 2021 in Colombia, were January 11: 32.7%, January 4: 31.0%, January 15: 28.9%, January 18: 22.4%, March 22: 21.1%, March 28: 20.7%  and February 17: 20.1%. Conclusion: an active search of infected people must be continued through the practice of a greater number of PCR and viral antigen and molecular tests. The latter has been reported by the EPS to show very high accuracy, which accelerates the result delivery process.

Keywords:

Downloads

Download data is not yet available.

Article Details

Author Biography

Jorge Enrique Díaz Pinzón, Secretaría de Educación de Soacha

. Ingeniero. Magister en Gestión de la Tecnología Educativa, Especialista en

Administración de la Informática Educativa. Docente de matemáticas e

Investigador. Secretaría de Educación de Soacha, Cundinamarca, Colombia.

orcid.org/0000-0002-8870-7769

References

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199-1207. doi: 10.1056/NEJMoa2001316 DOI: https://doi.org/10.1056/NEJMoa2001316

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu, Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3 DOI: https://doi.org/10.1016/S0140-6736(20)30566-3

Hoffmann, M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052 DOI: https://doi.org/10.1016/j.cell.2020.02.052

Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574-1581. doi: 10.1001/jama.2020.5394 DOI: https://doi.org/10.1001/jama.2020.4031

Docherty A, Harrison E, Verde C, Hardwick S, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. doi: 10.1136/bmj.m1985 DOI: https://doi.org/10.1136/bmj.m1985

Richardson S, Hirsch J, Narasimhan S, Crawford J, McGinn T, Davidson K, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775 DOI: https://doi.org/10.1001/jama.2020.6775

Petrilli C, Jones S, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, Tobin K, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. doi: 10.1136/bmj.m1966 DOI: https://doi.org/10.1136/bmj.m1966

Lewnard J, Liu V, Jackson M, Schmidt M, Jewell B, Flores J, et al. Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study. BMJ. 2020;369:m1923. doi: 10.1136/bmj.m1923 DOI: https://doi.org/10.1136/bmj.m1923

Wu A, Wang L, Yang Z, Ji S, Xa S, Cao Y, Jing Meng J, Ding X, Gold S, Jiang T, Cheng G. One year of SARS-CoV-2 evolution. Cell Host Microbe. 2021 Apr 14;29(4):503-507. doi: 10.1016/j.chom.2021.02.017 DOI: https://doi.org/10.1016/j.chom.2021.02.017

Díaz-Pinzón JE. Uso de modelo predictivo para la dinámica de transmisión del COVID-19 en Colombia. Repert Med Cir. 2020;29(Núm. Supl.1):34-44. doi: 10.31260/RepertMedCir.01217372.1056 DOI: https://doi.org/10.31260/RepertMedCir.01217372.1056

National Center for Immunization, Respiratory Diseases (NCIRD), Division of Viral Diseases. Interim Guidance for Antigen Testing for SARS-CoV-2 [Internet]. United State: Centers for Diseases Control and Prevention; 2020 [cited 2021 marzo 19]; Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html.

Ministerio de Salud y Protección Social. Lineamientos para el uso de pruebas en el laboratorio de salud pública (lSP) en el marco de la emergencia sanitaria por (covid-19) en Colombia. Colombia: Ministerio de Salud y Protección Social; 2020. p. 29.

Ministerio de Salud y Protección Social. Lineamientos para el uso de pruebas moleculares RT-PCR, pruebas de antígeno y pruebas serológicas para SARS-CoV-2 (COVID-19) en Colombia. Colombia: Ministerio de Salud y Protección Social; 2020. p.34.

Díaz Pinzón JE. Soporte técnico de simulación Phet en la enseñanza y aprendizaje de fracciones equivalentes. Rev Invest Univ Quindío (Col.). 2016;28(2):31-41 DOI: https://doi.org/10.33975/riuq.vol28n2.6

Díaz-Pinzón JE. Correlación y regresión lineal de la evaluación tiempo y puntaje con recurso interactivo flash. INNOVA Research Journal. 2017;2(10):1-8. doi: 10.33890/innova.v2.n10.2017 DOI: https://doi.org/10.33890/innova.v2.n10.2017.254

Díaz-Pinzón JE. Estudio de los resultados del contagio por COVID-19 a nivel mundial. Repert Med Cir. 2020;29(Núm.Supl.1):65-71. doi: 10.31260/RepertMedCir.01217372.1089 DOI: https://doi.org/10.31260/RepertMedCir.01217372.1089

Instituto Nacional de Salud. Coronavirus (COVID-2019) en Colombia [Internet]. Bogotá: Instituto Nacional de Salud; 2020 [citado 2021 marzo 19]; Recuperado de: https://www.ins.gov.co/Noticias/Paginas/Coronavirus.aspx

Díaz-Pinzón JE. Positividad y proporción para muestras por COVID-19 en Colombia. Repert Med Cir. 2020;29(Núm. Supl.1):127-130. doi: 10.31260/RepertMedCir.01217372.1134 DOI: https://doi.org/10.31260/RepertMedCir.01217372.1134

Citado por